Participant Recruitment

***Recruitment to GREAT ended in March 2016 with an impressive number of 537 participants enrolled in the study.***

We aimed to recruit 480 people with early-stage dementia between April 2013 and March 2016. In three years of networking, ingenuity and determination, 537 people with early-stage dementia agreed to take part in the study, of which 475 completed all the baseline assessment measures and got randomised. With this impressive sample size we will be able to provide rigorous evidence regarding the clinical and cost-efficacy of goal-oriented cognitive rehabilitation for people with early-stage dementia. This superb achievement could not have taken place without the time, effort and support of all the collaborating research sites in Bangor, Bath, Birmingham, Cardiff, Kent, London, Manchester and Newcastle. The Bangor site made the largest single contribution by recruiting over 100 participants!

Potential participants were identified by clinical staff working at a number of memory assessment services and old age mental health services across eight sites in England and Wales.

The involvement of clinical staff in the process of participant identification was fundamental for the success of the trial, as clinical staff are in the best position to identify patients who meet the inclusion criteria and inform them about the study.

Recruitment of study participants in some of the sites was supported by government-funded research networks that help research teams in delivering studies on time and in line with recruitment targets. We are working with the Health and Care Research Wales in Wales (earlier: NISCHR CRC) and with the NIHR Clinical Research Network in England. They helped to identify and contact potential participants in order to let them know about the study.

Who took part in the study?

We invited individuals who meet the following inclusion criteria:

  • ICD-10 diagnosis of Alzheimer’s disease (AD), vascular dementia, or mixed AD and vascular dementia
  • MMSE score of 18 or above (or equivalent)
  • Stable dose of cholinesterase inhibitors (if taken)
  • No history of other significant neurological conditions
  • Family member or close friend who is willing to participate
  • Capacity to give informed consent